Broad and One Mind scientists will use single-cell RNA sequencing technologies to investigate the role of microglia in Alzheimer's disease onset and progression.
Caris will use its suite of technologies to help Elevation Oncology enroll patients with NRG1 fusion-positive solid tumors to its Phase II trial of seribantumab.
GeneCentric and Erasmus will aim to identify RNA-based drug response markers for existing bladder cancer treatments, as well as discover novel targeted therapies.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging.
Roche, Shionogi, Janssen Pharmaceuticals, and Eisai will provide the charity with specimens from Alzheimer's disease patients who participated in clinical studies.
Spun out of Insilico Medicine in January, Deep Longevity is developing artificial intelligence-based systems to track aging based on various biomarkers.
RenalytixAI's flagship product is KidneyIntelX, which applies artificial intelligence to patient data to aid in the treatment of progressive kidney disease.
The company and the Harvard TH Chan School of Public Health will study the use of microbial biomarkers to identify precancerous adenomas and carcinomas in the colon.
The funding marks the second cycle of CZI's Essential Open Source Software program, which awards between $50,000 and $250,000 in total costs per project.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.
The study, which is being supported by Thermo Fisher Scientific, aims to identify genetic biomarkers that can predict patients likely to develop severe disease.
The HRM-based method developed by Chinese researchers could also serve as an alternative genetic test when other methods are unavailable or too expensive.
President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.
